Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24GOODWIN, R; DING, K; WALDE, D et al.Annals of oncology. 2010, Vol 21, Num 11, pp 2220-2226, issn 0923-7534, 7 p.Article

Third CECOG consensus on the systemic treatment of non-small-cell lung cancerBRODOWICZ, T; CIULEANU, T; KRZAKOWSKI, M et al.Annals of oncology. 2012, Vol 23, Num 5, pp 1223-1229, issn 0923-7534, 7 p.Article

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyCOUDERT, B; CIULEANU, T; PARK, K et al.Annals of oncology. 2012, Vol 23, Num 2, pp 388-394, issn 0923-7534, 7 p.Article

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyVAN CUTSEM, E; LI, C.-P; LIPP, R et al.British journal of cancer. 2014, Vol 111, Num 11, pp 2067-2075, issn 0007-0920, 9 p.Article

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP casesGOLFINOPOULOS, V; PENTHEROUDAKIS, G; MALAMOU-MITSI, V et al.Annals of oncology. 2012, Vol 23, Num 10, pp 2725-2730, issn 0923-7534, 6 p.Article

Biomarker analysis in a phase III study of pemetrexed― carboplatin versus etoposide―carboplatin in chemonaive patients with extensive-stage small-cell lung cancerSMIT, E. F; SOCINSKI, M. A; SZCZESNA, A et al.Annals of oncology. 2012, Vol 23, Num 7, pp 1723-1729, issn 0923-7534, 7 p.Article

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationFOUNTZILAS, G; CIULEANU, E; DIONYSOPOULOS, D et al.Annals of oncology. 2012, Vol 23, Num 2, pp 427-435, issn 0923-7534, 9 p.Article

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm studyDOUILLARD, J.-Y; OSTOROS, G; COBO, M et al.British journal of cancer. 2014, Vol 110, Num 1, pp 55-62, issn 0007-0920, 8 p.Article

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancerCIULEANU, T; TSAI, C.-M; MIDDLETON, G et al.Lung cancer. 2013, Vol 82, Num 2, pp 276-281, issn 0169-5002, 6 p.Article

A randomised double-blind placebo-controlled phase II study of AG1004 for control of chemotherapy-induced diarrhoeaCOYLE, V. M; LUNGULESCU, D; TOGANEL, C et al.British journal of cancer. 2013, Vol 108, Num 5, pp 1027-1033, issn 0007-0920, 7 p.Article

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003- 08004, RTOG 0212 and IFCT 99-01)LE PECHOUX, C; LAPLANCHE, A; WOLFSON, A et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1154-1163, issn 0923-7534, 10 p.Article

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m² 24 h or 1.3 mg/m² 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancerDEL CAMPO, J. M; ROSZAK, A; BIDZINSKI, M et al.Annals of oncology. 2009, Vol 20, Num 11, pp 1794-1802, issn 0923-7534, 9 p.Article

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG studyBRODOWICZ, T; CIULEANU, T. E; ZIELINSKI, C. C et al.Annals of oncology. 2013, Vol 24, Num 7, pp 1769-1777, issn 0923-7534, 9 p.Article

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerPEETERS, M; PRICE, T. J; STRICKLAND, A. H et al.Annals of oncology. 2014, Vol 25, Num 1, pp 107-116, issn 0923-7534, 10 p.Article